Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19

Indian J Pharmacol. 2021 May-Jun;53(3):246-247. doi: 10.4103/ijp.IJP_33_21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Administration, Intravenous
  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Biomarkers / blood
  • COVID-19 / blood*
  • COVID-19 Drug Treatment*
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-6 / antagonists & inhibitors*
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Severity of Illness Index*
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • IL6 protein, human
  • Interleukin-6
  • itolizumab